The Global Recombinant Protein Market report includes a global opportunity analysis and industry forecasts for the period 2023-2032. The global market was valued at USD 2.99 billion in 2022, registering a CAGR of 12.04% from 2023 to 2032. The base year considered for the study is 2021, and the forecast has been provided for the period, 2023 to 2032.
The Global Recombinant Protein Market is anticipated to grow at a CAGR of 12.04% during the forecast period. Recombinant Proteins is resulting as of an expression of recombinant DNA (rDNA), within living cells of the patient’s body, are known as recombinant proteins. rDNAs are the DNA molecules that are formed by the research laboratory processes of genetic recombination, to bring genetic material together to form multiple causes. DNA structures used to construct recombinant DNA molecules investigated from any kind. If the DNA sequences do not occur in nature, they can be created through the chemical combinations of DNA, further incorporating them into recombinant molecules. DNA is the collection of patient samples from the respective body to generate health information and the transformation of data into a clear aspect, an actionable database of patients that are then used by pathology laboratories to optimize the clinical results. This operates on a population by identifying and tracking tissues within the body structure of individual patients. Recombinant protein provides disease management, closing care gaps, and better health outcomes.
Recombinant Protein Market Statistics
Government support for the prevention of bacterial diseases and rising geriatric diseases population and this resultant in an increase in infected disease prevalence, the need for affordable treatment options, and digitalization of healthcare systems are factors that will propel the global recombinant protein market during the forecast period. Furthermore, Lack of data management expertise and skilled analysts, reluctance to move from legacy systems and safety concerns concerning patient information are some of the major constraints on recombinant protein market growth.
Recombinant protein is technologically advance and is designed specifically to improve health outcomes at any point. Moreover, in the real world, practical applications of these technologies can improve the individual’s health and drive better outcomes of the population as a whole. The technological advancement in population health extends beyond big data applications for quality assessment and benchmarking capabilities. Also, technology enables the rapid aggregation of individual patient’s data to identify significant patterns in large populations. Advancement in technology that supports recombinant protein like to maintain patient dashboard, automated care management outreach, remote patient monitoring clinical grade, data aggregation, clinical intelligence/analytics, telemedicine, patient engagement, risk stratification. Therefore, the effect of this factor on the recombinant protein market is expected to increase soon with continuously evolving technologies.
Key Factors Impacting the Growth of recombinant protein market:
- Technological advancements
- To track and analyze competitive developments
- Helps in data security and data integration
- Cloud computing technology will safeguard patient data
- Digitalization of healthcare systems
- To forecast revenue of the market segments
Recombinant Protein Market By Segmentation (2017-2028)
The recombinant protein market segmentation is based on type, application, end-users, and region.
Type Outlook:
As per the current market consequence, the hormone segment has covered the largest recombinant protein market share and is projected to register a higher CAGR during the forecast period.
Application Outlook:
The application for the generation of revenues in the global recombinant protein market is drug discovery & development. The drug discovery & development segment is predicted to account for the largest share in recombinant protein market.
End User Outlook:
Based on end user, the recombinant protein market has been segmented into biopharmaceuticals companies, academics & research institute and others. In 2018, the biopharmaceuticals segment accounted for the largest share in the recombinant protein market.
Regional Outlook:
Based on the region, the global recombinant protein market has been segmented by North America, Western Europe, Eastern Europe, Asia Pacific, Middle East, & Rest of the World. In terms of revenue, North America is predicted to steer the worldwide recombinant protein market, due to the increasing expenditure in research. The US is anticipated witnessing the very best growth, due to the most important concentration of world-class research universities and academic medical centers. The R&D spending of the US is around 2.7% of its gross domestic product (GDP). In 2014, the US was leading the R&D investments in biotechnology and, since then, the US biotechnology research and investment has been growing at a gentle rate. The event of the latest products and collaboration activities of biotechnology companies is probably going to spice up the expansion of the recombinant protein market.
The report analyzes factors affecting the recombinant protein market from both demand and supply side and further analyses market dynamics affecting the market during the forecast year such as driver, restrain, opportunities and future trends. The report also provides comprehensive Porter’s model analysis on the recombinant protein market for all six regions namely; North America, Western Europe, Eastern Europe, Asia Pacific, Middle East and the Rest of the world.
Recombinant Protein Market By Regional Analysis (2017-2028)
Competitive Landscape
Innovative advancement in recombinant protein helps to maintain patient and group health track record to improve patient engagement, data aggregation, and remote monitoring. Major companies are investing in research and development. Key market players are also adopting inorganic development strategies like as acquisition of local brands. Similarly, other business models such as joint venture and market entry strategies are helping prominent vendors to make their presence felt in the recombinant protein market and increase their product portfolio. The key leading players in the market include Merck KGaA, New England Biolabs Inc., Thermo Fisher Scientific Inc., Dickinson & Company, Becton, Agilent Technologies, Inc., Lucigen Corporation, QIAGEN N.V., Takara Bio Inc., Lonza Group Ltd., Bio-Rad Laboratories, Inc., GenScript Biotech Corporation, Synthetic Genomics Inc., Promega Corporation, and New England Biolabs Inc.
This report also includes the profiles of key recombinant protein market companies along with their SWOT analysis and market strategies. In addition, these competitive landscapes provide a detailed description of each company including future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launch, new product developments, and other latest industrial developments.
Key Developments in Recombinant Protein Market:
- In August 2018, Allscripts Healthcare, LLC announced that the Electronic Healthcare Network Accreditation Commission has received accreditation from the Healthcare Network Accreditation Program for Payerpath and ePAP accreditation for ePrescribe.
- In May 2018, the Department of Veterans Affair announced an agreement with the Cerner Government Growth Factor-a subsidiary of Cerner-to use its service that will offer veteran care providers access to their medical history through EHRs.
- In April 2017, McKesson Corporation announced the completion of the acquisition of CoverMyMeds LLC-a developer of Electronic Prior Authorization (ePA) solutions. It also automates the process of prior authorization for more than 500 EHR systems, 700,000 suppliers, 49,000 pharmacies, most health plans and Pharmacy Benefit Managers (PBMs).
- In December 2017, Royal Philips acquired VitalHealth, in an effort to expand its presence in the field of population health, offering Biopharmaceutical Production recombinant protein solutions.
Recombinant Protein Market Timeline (2017-2028)
What Does This Report Provide?
This report provides a detailed understanding of the global recombinant protein market from qualitative and quantitative perspectives during the forecast period. The report also provides dynamic indicators with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market.
Market Segmentation:
By Type
- Hormone
- Growth Factor
- Enzyme
- Antibody
- Other
By Application
- Drug Discovery & Development
- Biopharmaceutical Production
- Other
By End User
- Biopharmaceuticals Companies
- Academics & Research Institute
- Others
By Region:
North America
- By Country (US, Canada, Mexico)
- By Type
- By Application
- By End User
Western Europe
- By Country (Germany, UK, France, Italy, Spain, Rest of Western Europe)
- By Type
- By Application
- By End User
Eastern Europe
- By Country (Russia, Turkey, Rest of Eastern Europe)
- By Type
- By Application
- By End User
Asia Pacific
- By Country (China, Japan, India, South Korea, Australia, Rest of Asia Pacific)
- By Type
- By Application
- By End User
Middle East
- By Country (UAE, Saudi Arabia, Qatar, Iran, Rest of Middle East)
- By Type
- By Application
- By End User
Rest of the World
- By Region (South America, Africa)
- By Type
- By Application
- By End User
Reasons to Buy This Report:
- Market size estimation of the recombinant protein market on a regional and global basis
- Unique research Usage for market size estimation and forecast
- Profiling of major companies operating in the market with key developments
- Broad scope to cover all the possible segments helping every stakeholder in the market
Customization:
We provide customization of the study to meet specific requirements:
- By Segment
- By Sub-segment
- By Region/Country
For more information, contact: sales@quincemarketinsights.com